CD40 and carcinoma: Our demonstration of the ability of adenovirus-delivered CD40L to suppress proliferation and induce apoptosis in carcinoma cells provides further rationale for exploiting the CD40-CD40L pathway for the treatment of solid tumours and suggests an advantage over other immunostimulatory cancer therapy approaches, particularly through generation of a membrane-bound mutant and through enhanced delivery via a conditionally-replicating vector.